Genetics

Takara Bio Launches First Commercial Dissolvable Microfluidic Lentiviral Transduction Enhancer

Retrieved on: 
Monday, May 6, 2024
Research, Medical Supplies, Genetics, Health Technology, Biotechnology, Other Health, Health, Other Science, Science, School, University, International Society, North Carolina State University, Cell, Biomedical engineering, Abstract, UCL, Biomedicine, Lentivirus, Booth, Gene, Society, ISCT, Associate, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.
  • With an easy, walkaway workflow, the Lenti-X Transduction Sponge achieves high transduction efficiency in any cell type, enabling downstream research applications in the gene and cell therapy space.
  • “The Lenti-X Transduction Sponge will transform the viral transduction landscape with its simple yet elegant design,” said Carol Lou, President & CEO of Takara Bio USA.
  • At ISCT, attendees can engage with Takara Bio during the poster presentation (Abstract #1133) and view the Lenti-X Transduction Sponge at Booth #721.

bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Bank of America, Bluebird, BofA Securities, Conference, Bluebird bio

bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m.

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m.
  • In addition, members of the management team will participate in the following upcoming investor conferences:
    BofA Securities 2024 Health Care Conference, Thursday, May 16, at 10:00 a.m. PT (1:00 p.m.
  • ET in Miami Beach, FL
    To access the live webcasts of bluebird bio’s first quarter results conference call and fireside chats, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com .
  • Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

BostonGene and the Medical College of Wisconsin Announce the Publication and Journal Cover Feature in Gastroenterology Highlighting Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Science, Education, Oncology, Cancer, Pancreas, Pancreatic cancer, MCW, Prognosis, Immunotherapy, Tumor microenvironment, Intelligence, Disease, Liver, Patient, Human, Fibrosis, Gene expression, Multimedia, Manuscript, Immune system, Medical director, Medical college, Gastrointestinal disease, TME, Pharmaceutical industry

BostonGene’s artwork was also chosen for the cover of the May publication.

Key Points: 
  • BostonGene’s artwork was also chosen for the cover of the May publication.
  • The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition.
  • The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies.
  • “For a long while, the scientific community believed that pancreatic cancer was not responsive to immunotherapy, which uses a person’s own immune system to fight cancer.

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

Retrieved on: 
Tuesday, May 7, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dicarboxylic acid, Metadata, DSM-IV codes, CRISPR, DOI, Safety, LAMA1, LAMA2, AAV, Tokyo Stock Exchange, DNA, Therapy, Patient, Congenital muscular dystrophy, Gene expression, Manuscript, BioRxiv, Vaccine

The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.

Key Points: 
  • The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.
  • LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein.
  • No approved therapies to address the root cause of this condition exist or are in clinical trials.
  • "We are thrilled to post our comprehensive preclinical data supporting the development of MDL-101 on bioRxiv.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
Monday, May 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

American Single Malt Specialist Bird Creek Nets Best Of Category, Double Gold In Prestigious Spirits Competitions

Retrieved on: 
Wednesday, May 8, 2024
Genetics, Ageing, Bird Creek, Map, Stell, Taste, Gold medal, Farmer, High desert, Disease, Gold, Small batch whiskey, Fungal infection, ADI, Coffee, Barrel, Cask strength, Beer

PORTLAND, Ore., May 8, 2024 /PRNewswire-PRWeb/ -- Bird Creek Whiskey, an up-and-coming American single malt distillery focused on rare types of malted barley-influenced whiskeys, finds itself in the enviable position of netting coveted awards in highly acclaimed, back-to-back spirits competitions, having been awarded multiple top-flight medals and accolades at the 2024 San Francisco World Spirits Competition and ADI's 2024 International Spirits Competition. These Best of Category, Double Gold, and Gold nods have quickly put this exclusive whiskey maker on the map.

Key Points: 
  • These Best of Category, Double Gold, and Gold nods have quickly put this exclusive whiskey maker on the map.
  • Our quality begins at the farm, followed by a team working to produce the best American single malt without exception."
  • For ADI's 2024 International Spirits Competition, Bird Creek took Best of Category American Single Malt, Bottled & Blended, for its flagship Small Batch American Single Malt.
  • Our quality begins at the farm, followed by a team that works to produce the best possible American single malt without exception.

Andall Biosciences Introduces 23WELL: A Breakthrough New Brand with Ovary Care Capsules (1+1) as its Stellar Debut Product

Retrieved on: 
Wednesday, May 8, 2024
FDA, Capsule, Genetics, ABI, Woman, Food, Dietary supplement, Health, Medicine, Collection, Inositol, Research, Disease, Incidence, Coenzyme Q10, CAC, Multimedia, Codex Alimentarius, POI, Primary ovarian insufficiency, Certificate, Global health

The brand takes center stage with its debut offering, Ovary Care Capsules (1+1) at Circle Harmony, a high-end medical service institution located within InterContinental Shanghai Ruijin.

Key Points: 
  • The brand takes center stage with its debut offering, Ovary Care Capsules (1+1) at Circle Harmony, a high-end medical service institution located within InterContinental Shanghai Ruijin.
  • This revolutionary new product, 23WELL Ovary Care Capsules (1+1), is dedicated to women's health, specifically ovary care.
  • With 23WELL, ABI delivers a brand that not only represents premium quality but also champions the pursuit of optimal health.
  • 23WELL introduces its Ovary Care Capsules in a special 1+1 offer, uniquely blending the best of Western and Chinese medicinal traditions.

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

Retrieved on: 
Tuesday, May 7, 2024
Doctor of Philosophy, Brain, Traffic barrier, Mouse, Phenotype, Poster, MD, Model, Cell, Deficit spending, Associate professor, STXBP1, AAV, DSM-IV codes, Vivisection, Genetics, Disease, Patient, Liver, Baylor College of Medicine, Society, Gene, Treatment, Neurology, Seizure, Gene expression, Neuron, Annual general meeting, Texas Children's Hospital, Baylor University, Baltimore Convention Center, Vaccine

THOUSAND OAKS, Calif., May 7, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida's gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

Key Points: 
  • Gene therapy for genetic epilepsy due to STXBP1 mutations has not been previously possible because earlier generation adeno-associated viruses (AAVs) or wild-type AAVs could not achieve the level of widespread neuronal transduction required to modify the disease.
  • CAP-002 is a first-in-class next-generation intravenous (IV)-administered gene therapy that achieves brain-wide neuronal expression while simultaneously detargeting the liver.
  • Capsida's wholly owned program is currently in IND-enabling studies and is expected to enter the clinic in the first half of 2025.
  • This level of gene expression raises neuronal STXBP1 protein to levels comparable to those that reversed disease phenotype in the mouse model.

New Texting Program Helps Families Navigate a Hearing Loss Diagnosis in Infants and Toddlers

Retrieved on: 
Monday, May 6, 2024
Brain, University, American Speech–Language–Hearing Association, Genetics, Language, Text, Hearing, HEAR, News, Pregnancy, Hearing loss, Communication, Doctor of Philosophy, Parent, Audiology, Infant, CCC, Doctor of Audiology, Speech, Documentation, Family, ASHA, MPH, Noise, Caregiver, Ear, Collaboration, Child, Infection, Idaho State University, Anatomical pathology

ROCKVILLE, Md., May 6, 2024 /PRNewswire/ -- A new text messaging program announced today by the American Speech-Language-Hearing Association (ASHA), Bright by Text, and the Helping Adults Talk to Children (HATCH) Lab at Idaho State University will put trusted information into the hands of families with children who have—or may have—hearing loss.

Key Points: 
  • A hearing loss diagnosis can be scary, overwhelming, and isolating for parents of infants and toddlers.
  • More than 90% of deaf children are born to parents who hear, which can make the news of a hearing loss very unexpected.
  • "A hearing loss diagnosis can be scary, overwhelming, and isolating for parents of infants and toddlers—particularly if hearing loss doesn't run in the family," said Tena McNamara, AuD, CCC-A/SLP, 2024 ASHA President.
  • Left unaddressed in infants and toddlers, hearing loss (even a mild hearing loss) can lead to delays in speech, language, and cognitive development.

Mars, Incorporated Enters Exclusive Discussions to Acquire the Entire Stake in French Veterinary Diagnostics Businesses Cerba Vet and ANTAGENE Held by the Cerba HealthCare Group

Retrieved on: 
Friday, May 3, 2024
Veterinary, Biotechnology, Pets, Health, Medical Devices, Wearables, Mobile Technology, Technology, Consumer, Genetics, Laboratory, Pet, Biodiversity, Veterinarian, Hematology, Endocrinology, Serology, Growth, Cat, DNA, Science, Microbiology, Chemistry, Acquisition, Dog, Horse, Veterinary medicine

Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.

Key Points: 
  • Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
  • Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland.
  • Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
  • Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.